'The Global Advanced Wound Care Market Will be Worth $16.3bn by 2023' Says Visiongain Report

Informations

• Publié par: visiongain
• Nombre de lectures: 11
• Langue: English

Extrait

'The Global Advanced Wound Care Market Will be Worth $16.3bn by 2023' Says Visiongain Report

PR Newswire LONDON, December 10, 2012

LONDON,December 10, 2012/PRNewswire/ --

A new report byvisiongain, a London-based business information provider predicts the global advanced wound care market to be worth$16.3bnby 2023. The market generated$6.5bnin 2011, according toAdvanced Wound Care: World Market Prospects 2013-2023, published inNovember 2012. Clinicians and patients now prefer advanced products over the traditional ones, as they are more efficient in wound healing and reducing hospital stays. The advanced wound caremarketis expected to achieve strong growth in the future, driven by an aging population, and increasing prevalence of diabetes and obesity leading to more chronic wounds.

Amritha.M.Ramakrishnan, healthcare industry analyst says "The advanced wound care products have become physicians' preferred choice for treatment of chronic wounds. New product launches, increased penetration of existing products into developing countries and technological advancements will drive future growth. In the recent years, advanced wound care products have enjoyed strong growth mainly driven by moist wound care products and to a small extent by wound care devices and biologics. Most of the research is now being focused on wound care devices and biologics, as the moist wound care market is saturated. Wound care devices, particularly N PWT have a strong place in the advanced wound care market. How ever, further growth in this market will be driven by low cost and easy to use models. At present, wound care biologics is the most immature market. Although, some of the biologic products have proven to be more effective than other treatment methodologies, the cost to the consumer and lack of clinical evidence are major issues. With the advanced wound care market becoming more and more competitive, the market will be driven by more cost effective and clinically significant products".

Visiongain's research suggests that the advanced wound care market will also benefit from the growth of emerging economies. Countries including China and India are already witnessing an increase in lifestyle related disorders such as diabetes and obesity, along with increasing spending power. In the near future, mature markets such as the US and EU will drive the adoption of novel wound care devices and biologics, which command high prices in the market. Wound care biologics are still to achieve the attention they deserve, since the high cost of treatment has prevented their wide scale use. However, the market for wound care biologics will witness strong growth as their cost-effectiveness becomes evident.

Visiongain's analysis of the moist wound care, wound care devices and wound care biologics pipelines shows a number of innovative products with a great deal of promise. This new report adds to visiongain's wide range of analytical reports in healthcare and other industry areas.

For sample pages and further information concerning the visiongain Advanced Wound Care: World Market Prospects 2013-2023 report please visit:http://www.visiongain.com/Report/940/Advanced-Wound-Care-World- Market-Prospects-2013-2023

Companies Listed 3M Acell AcryMed Activa Health Care Advanced Medical Solutions Agennix Anika Therapeutics AOTI Argentum Medical ArjoHuntleigh Armed Forces Institute of Regenerative Medicine (AFIRM) Arobella Medical Avita Medical Biofisica Biolight AB B.Braun Boehringer Ingelheim Brennen Medical BSN Medical Gmbh Cardium Therapeutics

Catrix Celleration Centre for Devices and Radiological Health (CDRH) Collagen Matrix Coloplast ConvaTec Cornell University Covalon Technologies Covidien Curatec Curasan Cytomedix Derma Sciences Deroyal Devon Medical Products Diapulse Corporation of America Dr. Suwelack Skin & Healthcare Dow-Hickam Eucare Pharmaceuticals Ferris Fibrogen Fidia Advanced Biopolymers Food and Drug Administration (FDA) Forticell Bioscience Fraunhofer Institute Garnet Biotherapeutics Genadyne Biotechnologies Genzyme Biosurgery Getinge Greystone Pharmaceuticals Hartmann Group Healthpoint Biotherapeutics HemCon Medical Technologies Hollister Wound Care Human Biosciences HydroFera Innovative Therapies Ingenious Technologies Corporation Integra Life Science Corp International Diabetic Federation (IDF) Innocoll Italian National Health Service IYIA Technologies Johnson & Johnson Kaken Pharmaceuticals Kalypto Medical Kinetic Concepts Kuros Biosurgery Lifecell Lightwave Technologies Lescarden Lohmann & Rauscher Macrocure Marine Polymer Technologies Inc McGowan Institute for Regenerative Medicine Medestea Internazionale MediWound Medline Industries MiMedX Ministry of Health, Labour and Welfare (MHLW) Misonix Missouri S&T and Mo-Sci Corporation Molnlycke Nara University, Japan National Competent Authorities (NCA) National Health Service (NHS) Nanotherapeutics NanoVibronix Noble Biomaterials Oculus Innovative Sciences Organogenesis Osiris Therapeutics Oxygen Biotherapeutics Phytoceuticals

Polyheal Polynovo Biomaterials Promethean LifeSciences Prospera Quick Med Technologies RedDress RegeneRx Biopharmaceuticals Regenesis Biomedical SafeBlood Technologies Sangui BioTech International Sanuwave Health Shire Regenerative Medicine Smith & Nephew Soring Spiracur Synapse Microcurrent Snyder Wound Research LLC Systagenix Talley Group Tissue Genesis Tissue Regeneration Technologies UC, Berkley UDL Laboratories ULURU United Nations (UN) University of Cincinnati University of Bath URGO Vibrant Medical Vario Vomaris Innovations Wellman Centre for Photomedicine, Harvard University Wound Management Technologies Wright Medical

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies inEurope. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

For an executive summary please contact: Sara Peerun,[e-mail], Tel: [phone]